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Abstract
Background: It has been suggested that the phenotypes of Behçet’s disease (BD) in Japan are changing. To ask
whether the evolution of BD holds true in recent-onset cases in Japan, we performed a retrospective study.
Methods: We reviewed the records of 578 patients with BD who met the 1987 revised diagnostic criteria of the Behçet’s
disease research committee of Japan. The patients were divided into three groups based on the date of disease onset.
We compared the demography, clinical features, and treatments among them with or without adjustment for the
observation period. Patients having oral ulcers, genital ulcers, regional skin involvement, and uveitis are categorized
as having complete-type BD, and the associated factors were determined by univariate and multivariate logistic
regression analyses.
Results: Male patients had a higher propensity for uveitis and central nervous system (CNS) involvement, whereas female
patients had higher rates of genital ulcers and arthritis. We found a significant trend in reduction of complete-type,
genital ulcer, HLA-B51 carriers, and increment of gastrointestinal BD over time. Multiple regression analysis identified
HLA-B51 positivity, earlier date of disease onset, and younger age of onset as independently associated with
complete-type BD. Although treatments had been also chronologically changed, the causative relationship between
therapeutic agents and phenotypical changes was not determined from the study.
Conclusion: The present study revealed that phenotypical evolution was characterized by decreased incidence of the
complete type and increment of gastrointestinal involvement in Japanese patients with BD during the last 30 years.
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Background
Behçet’s disease (BD) is an inflammatory disease of
unknown cause, affecting multiple organs such as eyes,
skin, mucosa, and brain [1]. A definitive environmental
factor associated with BD is still unknown. Microbes
such as Streptococcus sanguinis and herpes simplex have
been implicated in BD pathogenesis [2, 3], and genetic
evidence supporting association with microbiomes in the
development of BD is growing [4]. Moreover, dysbiosis
in the intestinal flora has been reported in many inflam-
matory diseases including BD [5, 6]. It is thus possible
that environmental factors modify the clinical courses
and phenotypes of BD.
Epidemiological studies from Japan and Korea have
shown that the prevalence of BD, particularly of patients
with serious manifestations, is decreasing [7–9]. We
previously reported that newly diagnosed complete-type
BD (patients having all four of the major symptoms of oral
ulcers, genital ulcers, and eye and skin lesions) in
Kanagawa district, Japan had been declining since the year
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2000, compared with the previous data (33 % of patients
diagnosed before 2000 had complete BD compared to
23 % of patients between 2000 and 2007) [8]. Similarly, a
recent paper from Korea also reported reduction in the
complete type, declining male propensity, and shifting
patterns of organ involvement, during the last 30 years
[9]. However, to our knowledge, such chronological
changes in the BD phenotype have been reported only in
Japan and Korea, where the majority of the residents have
been native and genetically homogenous, with infrequent
influx of immigrants from other ethnic groups. These
findings suggest the involvement of altered environmental
factors in the phenotypical changes in BD in these coun-
tries. To determine whether the trends were transient or
continuous in the same area, this study enrolled patients
newly diagnosed with BD after 2008 and compared them
with the previous cohorts reported by Ideguchi et al [8].
Methods
The patients who participated in the study met the 1987
revised diagnostic criteria of the Behçet’s disease
research committee, the Ministry of Health, Labor and
Welfare of Japan [10]. These patients had been treated
in any of the seven hospitals within the Kanagawa dis-
trict located in mid-Japan, from July 1991 to December
2015. All patients were Japanese except for four patients
(one Filipino, one Syrian, one Korean, and one Chinese
patient). The study was approved by the Ethic Commit-
tee of Yokohama City University (A141127010). The
study followed the Ethical Guidelines for Epidemiology
Research, published by the Japanese Ministry of Health,
Labor, and Welfare, applying the opt-out strategy. In
addition to patients who participated in the study re-
ported by Ideguchi, we extracted all of the patients with
a diagnosis of BD from the computerized medical re-
cords in the seven participating hospitals. Thereafter, dif-
ferent rheumatologists (YK Kirino, HK, AS Suda, Y
Kunishita, KM, TM, TW, YA, TU, RY, TY, and AS Seki-
guchi) reviewed the records for their clinical manifesta-
tions and treatment regimens.
Under the Japanese criteria, recurrent aphthous oral
ulcers, skin lesions, ocular inflammation, and genital ul-
cers are included in “major symptoms”, whereas arthritis,
intestinal ulcers, epididymitis, vascular lesions, and neuro-
psychiatric disease are included under “minor symptoms”.
The criteria classify clinical subtypes into complete and
incomplete types. The former includes patients with all
four major symptoms during the clinical course, whereas
the latter includes those having three major symptoms,
two major and wo minor symptoms, typical recurrent
ocular inflammation and one or more major symptoms,
or typical recurrent ocular inflammation and two minor
symptoms. Moreover, patients with central nervous
system (CNS) involvement, vascular, and gastrointestinal
(GI) region involvement were categorized as having
special-type BD, and were further defined as the neuro-
logic type, vascular type, and GI type, respectively.
To reduce the heterogeneity of patients with BD and
to be comparable with other BD studies, we also applied
International Study Group (ISG) criteria to our patients
[11]. We extracted the following variables from the
patients’ records; BD phenotype, sex, age of BD onset,
date of disease onset, HLA-B51 positivity, observation
period, and treatment with biologic agents.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6
(San Diego, CA, USA) and SPSS version 22 (IBM Japan,
Tokyo, Japan). Categorical variables were analyzed using
the chi-square test or Cochran–Armitage test. Continuous
variables were analyzed using the Student t test. Univariate
and forward stepwise multivariate logistic regression
analysis was performed with presence of complete-type BD
as the dependent variable. Sex and age of BD onset were
forced into into the model. Variables that were significant
in univariate analysis were further included in the multi-
variate analysis. A p value less than 0.05 was considered as
statistically significant.
Results
We first carefully examined patients’ records and identi-
fied 578 patients who met the 1987 revised Japanese BD
diagnostic criteria, including 412 patients reported in
the previous paper [8] (Fig. 1). The clinical characteris-
tics are shown in Table 1. Consistent with our previous
data [8], genital ulcers and arthritis were more frequent
in female patients, whereas eye disease and CNS involve-
ment were more common in male patients. There was
no difference in HLA-B51 positivity between male and
female patients: both had higher HLA-B51 positivity
Fig. 1 Scheme of the patients with Behçet’s disease who
participated in the study
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than the general Japanese population (about 15 %), indi-
cating that the estimated odds ratio of HLA-B51 positiv-
ity in BD was approximately 3.5 in this series.
As mentioned earlier, we had divided the patients into
two groups of patients diagnosed before 2000 and those
diagnosed between 2000 and 2007, in the previous paper
[8]. Therefore, in the current study, the patients were di-
vided into three groups; group A (before year 2000), group
B (between 2000 and 2007), and group C (after 2008, after
the publication by Ideguchi), according to the date of BD
diagnosis (Table 2). In the previous study there were sig-
nificant reductions in the frequency of the complete type,
of genital ulcers, skin involvement, and CNS involvement
in group B compared to group A [8]. As shown in Table 2
we confirmed that these trends were continuous after
2008. However, there was also significant differences in
the observation period among the three groups.
In our previous study the clinical picture was of BD
evolving even after achieving the definitive diagnosis and
of patients with a longer history of BD presenting with
more manifestations [8]. Thus, we next adjusted the
observation duration among the three groups by selecting
symptoms appearing within 4.5 years after the onset of
disease. Patients without data on the onset of individual
manifestations were excluded from the analysis (Table 3).
Even after the adjustment, the date-dependent reduction
in the complete-type BD and genital ulcers remained
statistically significant. In addition, there was a reduced
Table 1 Characteristic of patients with Behçet’s disease (BD) who were enrolled in the study
Characteristics All (n = 578) Male (n = 247) Female (n = 331) Pa
Age at onset (mean ± SD) 36.8 ± 12.4 35.2 ± 12.1 37.8 ± 12.0 0.013b
Observation period (mean ± SD) 9.2 ± 9.2 8.2 ± 7.6 9.6 ± 8.4 0.036 b
HLA-B51, n (%) 177/352 (50.3) 88/170 (51.8) 89/182 (48.9) 0.59
Oral ulcer, n (%) 572 (99.0) 246 (99.6) 326 (98.5) 0.11
Genital ulcer, n (%) 417 (72.3) 141 (57.3) 276 (83.4) <0.0001
Eye involvement, n (%) 356 (61.6) 181 (73.3) 175 (52.9) <0.0001
Skin involvement, n (%) 513 (88.8) 212 (85.8) 301 (90.9) 0.055
Arthritis, n (%) 301 (52.1) 104 (42.1) 197 (59.5) <0.0001
Epididymitis, n (%) 14 (2.4) 14 (5.7)
Gastrointestinal involvement, n (%) 71(12.3) 26 (10.5) 45 (13.6) 0.069
CNS involvement, n (%) 59 (10.2) 34 (13.8) 25 (7.6) 0.015
Vascular involvement, n (%) 46 (8.0) 25 (10.1) 21 (6.3) 0.097
Fulfilling ISG, n (%) 517 (89.4) 213 (86.2) 304 (91.8) 0.030
aMale vs. female groups. bAnalyzed using the unpaired t test. Other variables were analyzed using the chi-square test. CNS central nervous system, ISG
International Study Group criteria for BD. Significant results are highlighted in bold font
Table 2 Evolution of clinical phenotypes of Behçet’s disease in Japan before correction for the follow-up period




Group C Post 2008
(n = 91)
P
Observation time (years) 11.9 ± 9.3 6.3 ± 4.8 3.7 ± 2.2 <0.0001
Age at onset 36.9 ± 11.8 35.8 ± 13.1 37.6 ± 11.4 NS
Gender male, n (%) 134 (41.5) 76 (46.3) 37 (40.7) 0.80
HLA-B51, n (%) 107 (54.9) 48 (49.0) 16 (43.1) 0.061a
Complete type, n (%) 124 (38.4) 45 (27.4) 16 (17.6) <0.0001
Oral ulcer, n (%) 321 (99.4) 163 (99.4) 88 (96.7) 0.065
Genital ulcer, n (%) 246 (76.2) 116 (70.7) 55 (60.4) 0.0033
Eye involvement, n (%) 211 (65.3) 92 (56.1) 53 (58.2) 0.083
Skin involvement, n (%) 293 (90.7) 145 (88.4) 75 (82.4) 0.033
Arthritis, n (%) 166 (51.4) 87 (53.0) 48 (52.7) 0.75
Gastrointestinal involvement, n (%) 37 (11.5) 20 (12.2) 14 (16.5) 0.35
CNS involvement, n (%) 39 (12.1) 17 (10.4) 3 (3.3) 0.023
Vascular involvement, n (%) 26 (8.1) 17 (10.4) 3 (3.3) 0.35
aNot all of the patients were typed for HLA-B51 positivity. Significant results are highlighted in bold font. CNS central nervous system, NS not significant
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rate of HLA-B51 positivity and increased rate of the GI
type. There were no significant shifts in the rate of male
patients or age of disease onset, which are predisposing
factors to the severe BD phenotype [12, 13]. Although the
frequency of genital ulcers was significantly reduced in fe-
male patients (p = 0.025 compared p = 0.13 for male pa-
tients), this symptom was still more common in female
than in male patients.
All patients met the Japanese criteria in this study, but
61 patients (10.6 %) did not meet the ISG criteria (Table 1).
On the other hand, patients fulfilling the ISG criteria but
not the Japanese criteria were not enrolled found in our
cohort, because the ISG criteria list only four symptoms
besides a positive pathergy test, and phenotypical diversity
is more restricted than in the Japanese criteria. The fre-
quency of complete-type BD was chronologically reduced
or limited in patients fulfilling the ISG criteria (Table 3).
The frequency of patients with the GI type of BD have
been recently increasing. We and others have shown that
these patients have a lower frequency of HLA-B51 positiv-
ity, complete-type disease, and uveitis [14, 15], suggesting
that the GI type might have unique genetic and phenotyp-
ical features in comparison with patients who have other
subtypes of BD [16] (Additional file 1: Table S1). To exam-
ine whether recruitment of more patients with GI type BD
in group C could result in a reduction in the rate of
complete-type BD, we looked at the rates of the complete
type in patients without GI involvement. Even after
excluding these patients, there was a significant reduction
in the complete type (Table 3).
A meta-analysis has shown that HLA-B51 is associated
with male predominance and moderately higher prevalence
of genital ulcers, skin involvement, ocular involvement,
and decreased prevalence of GI involvement [14].
Therefore, a reduced rate of HLA-B51-positive patients
in our cohort could be implicated in the increased
frequency of the milder disease phenotype. However,
our data revealed that the phenotypical evolution was
found in HLA-B51-positive patients as well as in other pa-
tients (the rate of the complete type in HLA-B51-positive
cases was 46.6 % before 2000, 29.8 % in 2000–2007, and
31.8 % in 2008–2015), though the sample size was pre-
sumably too small (n = 172) to obtain a statistically signifi-
cant result (p = 0.062).
In the current study, patients were arbitrarily seg-
mented into three groups based on disease onset, which
may have resulted in skewed outcomes. In addition,
multiple factors mutually contribute to the reduced rates
of complete-type BD. To identify factors independently
associated with complete-type BD, we performed univar-
iate and multivariate logistic regression analyses, with
the complete type as a dependent variable. In multivari-
ate analysis, young age of onset, HLA-B51 positivity, and
earlier date of diagnosis were independently associated
with risk of developing complete-type BD (Table 4).
Change of treatment strategies, especially use of biologic
agents, during the last two decades could have profound
effects on the phenotypes of BD, as azathioprine has been
suggested to modify the natural clinical course [17]. In
Japan, the approval of infliximab (IFX) for uveitis in 2007,
and adalimumab (ADA) for the GI type in 2013, have
encouraged us to introduce biologic agents as early as
possible in serious cases. Early initiation of biologic agents
could suppress the appearance of additional symptoms,
Table 3 Evolution of clinical phenotypes of Behçet’s disease in Japan after correction for the follow-up period




Group C Post 2008
(n = 91)
P
Observation time (years) 3.52 ± 1.6 3.25 ± 1.7 3.7 ± 2.2 NS
Age at onset 36.4 ± 11.9 35.8 ± 13.0 37.6 ± 11.4 NS
Gender male, n (%) 121 (41.3) 74 (46.3) 37 (40.7) 0.81
HLA-B51, n (%) 103 (53.4) 47 (50.0) 16 (43.1) 0.031a
Complete type, n (%) 99 (33.8) 37 (23.1) 16 (17.6) 0.0008
Oral ulcer, n (%) 291 (99.3) 159 (99.4) 88 (96.7) 0.079
Genital ulcer, n (%) 219 (74.7) 112 (70.0) 55 (60.4) 0.0096
Eye involvement, n (%) 184 (62.8) 85 (53.1) 53 (58.2) 0.19
Skin involvement, n (%) 255 (87.0) 137 (85.6) 75 (82.4) 0.28
GI, n (%) 18 (6.1) 19 (11.9) 14 (16.5) 0.0036
CNS, n (%) 20 (6.8) 14 (8.8) 3 (3.3) 0.46
Vascular, n (%) 17 (5.8) 15 (9.4) 3 (3.3) 0.73
Complete type fulfilling, n ISG (%) 99/264 (37.5) 37/135 (27.4) 16/74 (21.6) 0.0037
Complete type w/o GI, n (%) 96/275 (34.9) 35/141 (24.8) 15/77 (19.5) 0.0030
Numbers of patients shown are different from Table 2 because 31 patients were excluded due to ambiguity of the date of phenotype expression. aNot all of the
patients were typed for HLA-B51 positivity. GI gastrointestinal, CNS central nervous system, w/o without, NS not significant
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leading to phenotypical changes in recently enrolled
patients in our cohort. We asked whether patients with
IFX or ADA had different phenotypes among groups A, B,
and C, but there were no significant differences among
the groups in the rates of patients with the complete or GI
type who were receiving TNF inhibitors, in spite of the
increasing number of users (Additional file 2: Table S2).
Patients who required anti-TNF therapy had already been
found to have a mature BD phenotype at the start of
therapy.
It is also possible that earlier detection of BD may lead to
early intervention, resulting in a milder disease phenotype.
However, there was no difference among the groups in the
age of disease onset. Moreover, we have collected data on
the use of prednisolone, colchicine, azathioprine, calcine-
urin inhibitors, methotrexate, and non-steroidal anti-
inflammatory drugs (NSAIDs) in 456 patients for whom
treatment data were available. As shown in Additional file
3: Table S3, we found that use of calcineurin inhibitors was
decreased, while other drugs were increased. The results
suggest that change of treatment strategy could have
affected the BD phenotype in our patients. These data
collectively indicate that the phenotype of BD is evolving in
patients with recent onset of BD in our district.
Discussion
In the present study, we observed a continuous reduction
in complete-type BD in our district since the previous
report in 2007 [8]. Moreover, we a reduced rate of genital
ulcers, reduction in HLA-B51-positive patients, and in-
creased prevalence of the GI type have persisted. Of these,
HLA-B51 was found to be associated with the complete
type in multivariate analysis. Therefore, it is likely that the
decreased proportion of HLA-B51-positive patients is
partially responsible for the recent phenotypical change,
though a trend towards decline in the complete type was
also observed in HLA-B51-positive patients. Although
increment of the GI type, which was negatively associated
with the complete type, was one of the important conse-
quences in this study, it did not directly result in reduction
in the complete type in our analysis. Of note, the analysis
confirmed that the complete type was associated with an
earlier date of BD onset. A similar evolution of the BD
phenotype has been reported, not only in the Yokohama
area, but also in other parts of Japan [7, 18], and recently in
Korea [9]. Please change the ref3 to ref9 These data suggest
that change in the BD phenotype is ongoing in East Asia.
The reduction in HLA-B51-positive BD patients in our
cohort is intriguing. This phenomenon is difficult to
explain, because the pathogenic role of HLA-B51 in the
development of BD is not fully understood. Rather, our
data suggest that interaction between HLA-B51-restricted
immune responses and external factors is involved in the
disease process, and that altered environmental factors
attenuate the immune responses, resulting in reduced
prevalence and phenotypical changes to mild forms in
HLA-B51-positive individuals. Besides detailed molecular
analysis, clinical observations as in this study may also
contribute to understanding the pathogenesis of BD.
Several lines of evidence suggest that both genetic and
environmental factors are involved in the pathogenesis of
BD. An epidemiological study of immigration supports
the hypothesis that BD has a primarily hereditary basis
[19], while others report a significant impact of environ-
mental factors, including life style, on disease development
[20, 21]. Ethnic and regional differences in the clinical
phenotypes of BD also suggest genetic factors are impli-
cated in the clinical course after disease onset [22]. How-
ever, genetic backgrounds were highly preserved in a
series of the cohort studies, because we have evaluated
mostly Japanese patients. This was the case for other stud-
ies in Japan and Korea. Thus, it is likely that environmen-
tal factors contribute more to the phenotypical changes of
BD in this area than genetic factors.
As for environmental factors, microbial pathogens are
implicated in the development of BD [23]. Previously, we
raised the possibility that improved oral hygiene contributes
to the suppression of microbial pathogen-related immune
responses [8]. It has long been suggested that microorgan-
isms such as Streptococcus sanguinis provoke inflammation
Table 4 Univariate and multivariate logistic regression analysis with the complete type as a dependent variable
Univariate Multivariate
P Odds ratio 95 % CI P Odds ratio 95 % CI
Age of onset 0.024 0.98 0.97 1.00 0.049 0.98 0.96 1.00
Sex 0.275 0.82 0.58 1.17 0.26 0.77 0.49 1.22
Date of onset 1.1 × 10-5 0.37 0.24 0.58 0.02 0.50 0.28 0.90
Gastrointestinal 0.01 0.44 0.23 0.82
Central nervous system 0.038 1.78 1.03 3.08
Vascular 0.37 0.73 0.37 1.45
HLA-B51 5.4 × 10-4 2.21 1.41 3.46 4.5 × 10-4 2.27 1.44 3.59
Forward stepwise logistic regression analysis was performed. Gastrointestinal, central nervous system, and vascular Behçet’s disease were not selected in the
multivariate model
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in BD [2, 23–25]. Smoking and gingivitis have been shown
to be environmental factors, which potentially affect the
components of oral flora [26]. Interestingly, both factors are
also identified as predisposing factors in the development of
rheumatoid arthritis through the generation of citrullinated
peptides as autoantigens [27], though it seems unlikely that
the same molecular mechanism operates in BD. Unfortu-
nately, details of smoking were unavailable in this study.
BD flares are often caused by bacterial infection and
after dental care, also suggesting oral flora involvement
in the BD process [28, 29]. Moreover, our recent genetic
association study implicated innate immune receptors
involved in detecting microorganisms in the development
of BD [4]. It is possible that change in environmental
factors, such as resident microbial components, are alter-
ing functions of BD-susceptibility genes. However, which
microorganisms, if any, are responsible for inflammation
or reduction in the complete type in BD is unknown, and
there is no evidence showing such microbiome structural
alteration is actually occurring in Japan.
The present study showed that the factor most strongly
attributing to reduction in complete type BD was genital
ulcers, especially in female patients. Because it is likely
that the decrease in prevalence of genital ulcers is caused
by environmental factors, identification of the causative
factors would give us a good clue in understanding the
pathogenesis of BD.
The ISG criteria are one of the most commonly applied
in BD studies [11]. The ISG criteria and the Japanese
criteria use different sets of clinical information; the ISG
criteria do not include clinical manifestations, which are
listed as special types in the Japanese criteria, whereas the
pathergy test is not included in the Japanese criteria. In
spite of the discrepancy, the two previous independent
genome-wide association studies (GWAS) have identified
similar genetic architecture between Turkish BD (diag-
nosed using the ISG criteria) and Japanese BD (diagnosed
using the Japanese criteria), suggesting that patients diag-
nosed with the two different sets of criteria are comparable
[30, 31]. Indeed, the major conclusions of this study are not
altered or limited in patients fulfilling the ISG criteria.
Consistent with previous studies, we found that the GI
type was the only manifestation that increased among
the serious phenotypes. The most apparent difference
between the Japanese criteria and the ISG criteria lies in
the presence of the GI type. Our previous paper re-
ported that Japanese patients with GI-type BD fulfilled
the ISG criteria at a lower rate compared with those
with the non-GI type (with the GI type 70 % vs. 92 %
without the GI type) [16]. It is still under consideration
as to how to classify the GI type BD in patients who
have a typical deep ulcer in the ileocecal region, but do
not fulfill the ISG criteria. Our data suggest that due to
increment of the GI type in East Asia, such patients
should be followed carefully, as extensively discussed in
a report from Korea [32].
It has long been recognized that the incidence of
inflammatory bowel disease (IBD) such as Crohn’s disease
is rising in many countries, and may be attributed to
change to a high-fat diet [33]. In Japan, the prevalence of
Crohn’s disease increased from 2.9 per 100,000 persons in
1986 to 63.6 in 2005 [34]. Similar mechanisms might be
involved in the increased incidence of the GI type of BD.
Indeed, IL23R and IL10 have been identified in GWAS of
BD [30], which are well-established IBD loci, supporting
the notion that common mechanisms play roles in the
development of GI-type BD.
Increment of GI involvement was associated with
increased use of NSAIDs, suggesting that NSAIDs may be
a risk factor for GI involvement in BD and in IBD.
However, as significant association has been identified
between GI involvement and arthritis [16], NSAIDs might
be more frequently used in patients with GI-type BD
because of complicated arthritis. Thus, it is hard to make
conclusions about the cause-effect relationship between
NSAIDs and GI involvement in the present study.
In our cohort, chronological changes in therapy could
have affected the phenotypes and clinical course of disease.
However, care should be taken to interpret the data because
of possible bias caused by incomplete data collection, par-
ticularly in the early days. Moreover, the clinical diversity of
BD makes it difficult to assess the disease-modifying effect
of each therapeutic agent. It is hard to determine whether a
particular symptom does not appear as a natural course or
whether it has been suppressed by the preceding therapy.
Moreover, because most treatments were determined by
the attending physicians, the therapeutic scenario was not
consistent in patients having a particular symptom, even on
the same date.
Although we were unable to show significant effects of
biologic treatment on the evolution of the BD pheno-
type, it is possible that immunosuppressive treatment
prevented subsequent development of the complete-type
and special-type BD. In a placebo-controlled trial of
azathioprine, vascular involvement developed more fre-
quently in the placebo group [17]. In addition, a case of
vascular BD after termination of IFX was reported [35].
However, in the current study, we did not observe a sig-
nificant reduction in eye disease, vascular type, or CNS
involvement in BD; rather, there was increment of GI
BD (Table 3). Patients with eye disease and special-type
BD often require intensive immunosuppressive treat-
ments, but not for genital ulcers (usually treated by top-
ical or oral steroids). Because genital ulcers usually
precede special-type manifestations [8], it is unlikely that
recent therapeutic changes caused a reduction in genital
ulcers during recent decades. However, due to the
retrospective nature of our study, we cannot exclude the
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possibility of treatment effect on the evolution of the BD
phenotype. To address the question, future prospective
studies with larger sample size and longer observation
period are needed.
There are several limitations in the study. First, the
data were retrospectively collected, therefore were
subject to selection bias. Second, data on important
epidemiological factors such as smoking status, changes
in diet, and body mass index were not available in all the
patients. Third, because treatments were principally
determined by the individual attending physicians and
were not necessarily consistent among the patients, it
was hard to assess the influence of therapeutic regimens
on disease manifestations.
Conclusions
Our cohort study showed that a reduced rate of
complete-type and increased rate of GI-type BD are
continuous trends in East Asia. Because the genetic
background was consistently homogeneous in our study
population, it is likely that the time-dependent changes
were caused by environmental factors. Identification of
causative factors would give a clue in the establishment
of novel strategies to modify the clinical course and
suppress disease flares as prophylactic medicine.
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